<DOC>
	<DOCNO>NCT01206335</DOCNO>
	<brief_summary>The purpose study determine whether patient advanced cancer receive OHR/AVR118 solution injection skin achieve improvement quality life . Based previous study patient AIDS , possible benefit may include improved appetite strength ; weight gain , improve mood ; decrease fatigue .</brief_summary>
	<brief_title>Open Label Study With OHR/AVR118 Advanced Cancer Patients With Anorexia-Cachexia</brief_title>
	<detailed_description>Advanced cancer usually debilitate . There treatment available symptom advance cancer like loss appetite , decreased strength , fatigue , change mood . This Phase II , open label study OHR/AVR118 enable Sponsor gather data safety efficacy OHR/AVR118 patient population anorexia-cachexia . Patients age 18-85 advanced cancer ( exclude central nervous system [ CNS ] cancer ) may may receive chemotherapy , may eligible participate . The study drug , 4.0 mL , give subcutaneously day 28 day . Patients respond trial period dose eligible continue OHR/AVR118 physician believe would beneficial , safety concern raise .</detailed_description>
	<mesh_term>Anorexia</mesh_term>
	<mesh_term>Cachexia</mesh_term>
	<criteria>Histologically confirm solid tumor cancer , leukemia , lymphoma , multiple myeloma . Concurrent anticancer treatment , chemotherapy radiation therapy permit except neoadjuvant adjuvant program . Between age 1885 . Symptoms recurrent metastatic cancer anorexia predominant symptom , necessarily associate cachexia , attribute anemia , concomitant illness , obstruction loss organ function . Karnofsky performance status 40 % Palliative Prognostic Score ( PaP ) less 6 Patient expect able remain study protocol two month . Pretreatment laboratory data within 7 day enrollment : Hemoglobin &gt; 8.5 g/dL , stable dos ( hematocrit stable within 1 gram dose stable one month ) erythropoietin similar medication . Absolute neutrophil count ( ANC ) 1,500/mm3 . Platelets 50,000/mm3 . Total bilirubin 2.0 ALT AST 2.5 time ULN , , patient liver metastasis , 5 time ULN . Creatinine 1.5 mg/dL . Normal TSH Testosterone level determine . Voluntary write informed consent performance studyrelated procedure part normal medical care . Ability selfadminister subcutaneous medication assistant nurse available , keep compliance journal document injection home . If antidepressant , dose must stabilize least 30 day . Female patient postmenopausal , surgically sterilize , willing use acceptable method birth control ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . Male patient agree use acceptable barrier method contraception study Patient uncontrolled brain metastasis central nervous system disease . Patient mechanical , nonreversible reason able eat , potential develop malignant bowel obstruction course induction phase treatment , patient require PEG obstruction . Patient major surgery within four week enrollment . Patient uncontrolled concomitant illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia . In Investigator 's opinion , potentially interfere completion treatment accord protocol . Female patient pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Cancer Cachexia</keyword>
	<keyword>Anorexia</keyword>
	<keyword>Advanced Malignancies</keyword>
	<keyword>Weight Loss</keyword>
	<keyword>Fatigue</keyword>
	<keyword>Karnofsky</keyword>
	<keyword>C-Reactive Protein</keyword>
	<keyword>Simmonds Functional Assessment</keyword>
</DOC>